Transplant Immunology and Rejection
Transplant immunology studies how the recipient immune system recognizes and responds to a grafted organ or tissue from a genetically different donor, and how that response can damage the graft. Graft rejection is the immune-mediated injury that results when the recipient's T cells and antibodies attack donor tissue; understanding its mechanisms underpins the diagnosis, classification, and prevention of allograft loss.
Definition
Transplant immunology and rejection is the field concerned with the alloimmune response to transplanted tissue and the resulting graft injury, encompassing allorecognition, sensitization, T-cell- and antibody-mediated rejection, and the induction of donor-specific tolerance.
Scope
This area orients the immunological basis of solid-organ and tissue transplantation: how foreign histocompatibility antigens are recognized (allorecognition), how prior exposure primes the immune system (allosensitization), the cellular and humoral effector pathways that injure the graft, and the spectrum of rejection from acute to chronic and antibody-mediated forms. It also covers the converse goal of immune tolerance. It is a reference and educational map of concepts and is not a source of individualized clinical management.
Sub-topics
Core questions
- How does the recipient immune system distinguish donor tissue as foreign?
- What cellular and humoral pathways injure an allograft, and how do acute, chronic, and antibody-mediated rejection differ?
- Why are some recipients sensitized before transplantation, and how does that change risk?
- Can durable donor-specific tolerance be achieved without lifelong immunosuppression?
Key concepts
- Human leukocyte antigen (HLA) / major histocompatibility complex
- Allorecognition (direct and indirect)
- Allosensitization and donor-specific antibodies
- T-cell-mediated (cellular) rejection
- Antibody-mediated (humoral) rejection
- Acute versus chronic rejection
- Banff classification
- Immunological tolerance
Key theories
- Acquired immunological tolerance
- Billingham, Brent, and Medawar showed experimentally that exposure to foreign cells in early life can render an animal unable to reject later grafts from the same donor, establishing that tolerance to alloantigen is an acquired, antigen-specific state rather than a fixed property of the host.
- Allorecognition pathways
- Recipient T cells recognize donor antigen either directly, via intact donor MHC molecules on donor cells, or indirectly, via recipient antigen-presenting cells displaying processed donor peptides; these pathways drive different tempos and types of rejection.
Mechanisms
Rejection begins with allorecognition: recipient T cells respond to donor histocompatibility antigens presented either directly on donor cells or indirectly after processing by recipient antigen-presenting cells. Activated CD4 and CD8 T cells drive cellular rejection through cytotoxicity and inflammatory cytokines, while B-cell help generates donor-specific antibodies that bind graft endothelium, fix complement, and recruit effector cells in antibody-mediated rejection. Prior pregnancy, transfusion, or transplantation can sensitize a recipient so that memory responses accelerate injury. Over time, repeated immune injury combined with non-immune factors produces the fibrosis and vascular remodeling of chronic rejection. Tolerance represents the controlled alternative, in which regulatory mechanisms restrain the alloresponse.
Clinical relevance
The immunology of rejection is the conceptual basis for histocompatibility testing, antibody screening, allograft biopsy interpretation, and the rationale for immunosuppression. Reading rejection pathology and antibody data critically is central to understanding why allografts fail and how transplant outcomes are studied. This entry describes mechanisms and evidence and is not a basis for individual diagnostic or treatment decisions.
Epidemiology
Antibody-mediated rejection and chronic injury are now recognized as dominant contributors to late allograft loss in kidney transplantation, while non-adherence to immunosuppression compounds immunological risk; long-term graft survival has improved less than short-term survival, reflecting the persistence of chronic rejection.
History
Modern transplant immunology grew from Medawar's wartime work on skin-graft rejection and the 1953 demonstration of acquired tolerance by Billingham, Brent, and Medawar. The discovery of histocompatibility antigens and the introduction of effective immunosuppression made clinical transplantation routine, after which attention shifted to classifying rejection (the Banff system), recognizing antibody-mediated injury, and pursuing tolerance.
Debates
- How much of late graft loss is immunological versus non-immunological?
- Studies attributing failure largely to antibody-mediated rejection and non-adherence have reframed late loss as substantially alloimmune, but calcineurin-inhibitor toxicity and other non-immune injuries also contribute, and disentangling them in biopsies remains contested.
Key figures
- Peter Medawar
- Rupert Billingham
- Leslie Brent
- Philip Halloran
- Kim Solez
- Robert Colvin
Related topics
Seminal works
- billingham-1953
- nankivell-2010
- solez-2008
- loupy-2018
Frequently asked questions
- What is graft rejection?
- It is immune-mediated injury to a transplanted organ or tissue that occurs when the recipient's immune system recognizes donor tissue as foreign and mounts cellular and/or antibody responses against it.
- Why is HLA matching important in transplantation?
- HLA molecules are the principal targets of the alloimmune response, so greater donor-recipient HLA disparity and pre-existing antibodies against donor HLA raise the risk and severity of rejection.